yingweiwo

Amoxicillin-clavulanate potassium

Cat No.:V53461 Purity: ≥98%
Amoxicillin-clavulanate potassium is an antibiotic.
Amoxicillin-clavulanate potassium
Amoxicillin-clavulanate potassium Chemical Structure CAS No.: 74469-00-4
Product category: Antibiotic
This product is for research use only, not for human use. We do not sell to patients.
Size Price
500mg
1g
Other Sizes
Official Supplier of:
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text

 

  • Business Relationship with 5000+ Clients Globally
  • Major Universities, Research Institutions, Biotech & Pharma
  • Citations by Top Journals: Nature, Cell, Science, etc.
Top Publications Citing lnvivochem Products
Product Description
Amoxicillin-clavulanate potassium is an antibiotic. Amoxicillin-clavulanate potassium may be used for studying a variety of bacterial infections.
Biological Activity I Assay Protocols (From Reference)
References
[1]. Evans J, Hannoodee M, Wittler M. Amoxicillin Clavulanate. [Updated 2021 Dec 15].
Additional Infomation
A fixed-ratio combination of amoxicillin trihydrate and potassium clavulanate.
See also: Amoxicillin; Clavulanic acid (annotation moved to).
These protocols are for reference only. InvivoChem does not independently validate these methods.
Physicochemical Properties
Molecular Formula
C24H27KN4O10S
Molecular Weight
602.66
Exact Mass
602.108
CAS #
74469-00-4
Related CAS #
79198-29-1 (parent)
PubChem CID
23665637
Appearance
White to light yellow solid powder
Hydrogen Bond Donor Count
5
Hydrogen Bond Acceptor Count
12
Rotatable Bond Count
6
Heavy Atom Count
40
Complexity
919
Defined Atom Stereocenter Count
6
SMILES
CC1(C(N2C(S1)C(C2=O)NC(=O)C(C3=CC=C(C=C3)O)N)C(=O)O)C.C1C2N(C1=O)C(C(=CCO)O2)C(=O)[O-].[K+]
InChi Key
DWHGNUUWCJZQHO-ZVDZYBSKSA-M
InChi Code
InChI=1S/C16H19N3O5S.C8H9NO5.K/c1-16(2)11(15(23)24)19-13(22)10(14(19)25-16)18-12(21)9(17)7-3-5-8(20)6-4-7;10-2-1-4-7(8(12)13)9-5(11)3-6(9)14-4;/h3-6,9-11,14,20H,17H2,1-2H3,(H,18,21)(H,23,24);1,6-7,10H,2-3H2,(H,12,13);/q;;+1/p-1/b;4-1-;/t9-,10-,11+,14-;6-,7-;/m11./s1
Chemical Name
potassium;(2S,5R,6R)-6-[[(2R)-2-amino-2-(4-hydroxyphenyl)acetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid;(2R,3Z,5R)-3-(2-hydroxyethylidene)-7-oxo-4-oxa-1-azabicyclo[3.2.0]heptane-2-carboxylate
HS Tariff Code
2934.99.9001
Storage

Powder      -20°C    3 years

                     4°C     2 years

In solvent   -80°C    6 months

                  -20°C    1 month

Shipping Condition
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
Solubility Data
Solubility (In Vitro)
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
Solubility (In Vivo)
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.

Injection Formulations
(e.g. IP/IV/IM/SC)
Injection Formulation 1: DMSO : Tween 80: Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution 50 μL Tween 80 850 μL Saline)
*Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution.
Injection Formulation 2: DMSO : PEG300Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO 400 μLPEG300 50 μL Tween 80 450 μL Saline)
Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO 900 μL Corn oil)
Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals).
View More

Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO 900 μL (20% SBE-β-CD in saline)]
*Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution.
Injection Formulation 5: 2-Hydroxypropyl-β-cyclodextrin : Saline = 50 : 50 (i.e. 500 μL 2-Hydroxypropyl-β-cyclodextrin 500 μL Saline)
Injection Formulation 6: DMSO : PEG300 : castor oil : Saline = 5 : 10 : 20 : 65 (i.e. 50 μL DMSO 100 μLPEG300 200 μL castor oil 650 μL Saline)
Injection Formulation 7: Ethanol : Cremophor : Saline = 10: 10 : 80 (i.e. 100 μL Ethanol 100 μL Cremophor 800 μL Saline)
Injection Formulation 8: Dissolve in Cremophor/Ethanol (50 : 50), then diluted by Saline
Injection Formulation 9: EtOH : Corn oil = 10 : 90 (i.e. 100 μL EtOH 900 μL Corn oil)
Injection Formulation 10: EtOH : PEG300Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL EtOH 400 μLPEG300 50 μL Tween 80 450 μL Saline)


Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium)
Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose
Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals).
View More

Oral Formulation 3: Dissolved in PEG400
Oral Formulation 4: Suspend in 0.2% Carboxymethyl cellulose
Oral Formulation 5: Dissolve in 0.25% Tween 80 and 0.5% Carboxymethyl cellulose
Oral Formulation 6: Mixing with food powders


Note: Please be aware that the above formulations are for reference only. InvivoChem strongly recommends customers to read literature methods/protocols carefully before determining which formulation you should use for in vivo studies, as different compounds have different solubility properties and have to be formulated differently.

 (Please use freshly prepared in vivo formulations for optimal results.)
Preparing Stock Solutions 1 mg 5 mg 10 mg
1 mM 1.6593 mL 8.2966 mL 16.5931 mL
5 mM 0.3319 mL 1.6593 mL 3.3186 mL
10 mM 0.1659 mL 0.8297 mL 1.6593 mL

*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.

Calculator

Molarity Calculator allows you to calculate the mass, volume, and/or concentration required for a solution, as detailed below:

  • Calculate the Mass of a compound required to prepare a solution of known volume and concentration
  • Calculate the Volume of solution required to dissolve a compound of known mass to a desired concentration
  • Calculate the Concentration of a solution resulting from a known mass of compound in a specific volume
An example of molarity calculation using the molarity calculator is shown below:
What is the mass of compound required to make a 10 mM stock solution in 5 ml of DMSO given that the molecular weight of the compound is 350.26 g/mol?
  • Enter 350.26 in the Molecular Weight (MW) box
  • Enter 10 in the Concentration box and choose the correct unit (mM)
  • Enter 5 in the Volume box and choose the correct unit (mL)
  • Click the “Calculate” button
  • The answer of 17.513 mg appears in the Mass box. In a similar way, you may calculate the volume and concentration.

Dilution Calculator allows you to calculate how to dilute a stock solution of known concentrations. For example, you may Enter C1, C2 & V2 to calculate V1, as detailed below:

What volume of a given 10 mM stock solution is required to make 25 ml of a 25 μM solution?
Using the equation C1V1 = C2V2, where C1=10 mM, C2=25 μM, V2=25 ml and V1 is the unknown:
  • Enter 10 into the Concentration (Start) box and choose the correct unit (mM)
  • Enter 25 into the Concentration (End) box and select the correct unit (mM)
  • Enter 25 into the Volume (End) box and choose the correct unit (mL)
  • Click the “Calculate” button
  • The answer of 62.5 μL (0.1 ml) appears in the Volume (Start) box
g/mol

Molecular Weight Calculator allows you to calculate the molar mass and elemental composition of a compound, as detailed below:

Note: Chemical formula is case sensitive: C12H18N3O4  c12h18n3o4
Instructions to calculate molar mass (molecular weight) of a chemical compound:
  • To calculate molar mass of a chemical compound, please enter the chemical/molecular formula and click the “Calculate’ button.
Definitions of molecular mass, molecular weight, molar mass and molar weight:
  • Molecular mass (or molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
  • Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.
/

Reconstitution Calculator allows you to calculate the volume of solvent required to reconstitute your vial.

  • Enter the mass of the reagent and the desired reconstitution concentration as well as the correct units
  • Click the “Calculate” button
  • The answer appears in the Volume (to add to vial) box
In vivo Formulation Calculator (Clear solution)
Step 1: Enter information below (Recommended: An additional animal to make allowance for loss during the experiment)
Step 2: Enter in vivo formulation (This is only a calculator, not the exact formulation for a specific product. Please contact us first if there is no in vivo formulation in the solubility section.)
+
+
+

Calculation results

Working concentration mg/mL;

Method for preparing DMSO stock solution mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.

Method for preparing in vivo formulation:Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.

(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
             (2) Be sure to add the solvent(s) in order.

Clinical Trial Information
eXtended Antibiotic Prophylaxis for Intermediate- and High-risk Glands After Pancreatoduodenectomy to Reduce CR-POPF
CTID: NCT05753735
Phase: Phase 2    Status: Terminated
Date: 2024-09-24
LiveSpo Navax® Supports the Treatment of Acute Rhinosinusitis and Otitis Media
CTID: NCT05804123
Phase: N/A    Status: Completed
Date: 2024-08-22
A Trial Investigating Lu AF28996 in Healthy Adult Participants
CTID: NCT06277609
Phase: Phase 1    Status: Completed
Date: 2024-06-11
Routine Antibiotic vs. Directed Antibiotic Treatment in Snake Bite
CTID: NCT02570347
Phase: Phase 4    Status: Terminated
Date: 2024-04-30
Autoflor -Lyophilized Capsulated Autological FMT to Restore Gut Microbiome After Treatment With Antibiotics
CTID: NCT06250413
Phase: N/A    Status: Not yet recruiting
Date: 2024-02-14
View More

Collaborative Urological Prosthetics Investigation Directive Research Group
CTID: NCT05100654
PhaseEarly Phase 1    Status: Active, not recruiting
Date: 2024-02-07


Prophylactic Antibiotic in Non-complicated Low Risk Lap Cholecystectomy (LC)
CTID: NCT06193837
Phase:    Status: Not yet recruiting
Date: 2024-01-05
Initial Non-operative Treatment Strategy Versus Appendectomy Treatment Strategy for Simple Appendicitis in Children
CTID: NCT02848820
Phase: Phase 4    Status: Active, not recruiting
Date: 2023-10-23
Antibiotic Prophylaxis and Renal Damage In Congenital Abnormalities of the Kidney and Urinary Tract
CTID: NCT02021006
Phase: Phase 3    Status: Active, not recruiting
Date: 2023-09-28
Effects of Antibiotic Prophylaxis on the Healing Parameters Following Surgical Crown Lengthening
CTID: NCT05925179
Phase: Phase 4    Status: Not yet recruiting
Date: 2023-07-19
Preschool Wheeze: Inflammation/Infection Guided Management
CTID: NCT02517099
Phase: Phase 2    Status: Completed
Date: 2023-03-06
EBA, Safety and Tolerability of Sanfetrinem Cilexetil
CTID: NCT05388448
Phase: Phase 2    Status: Unknown status
Date: 2022-05-24
Oral Steroids in Chronic Rhinosinusitis Without Nasal Polyps
CTID: NCT02927834
Phase: N/A    Status: Completed
Date: 2020-12-29
Preoperative Dose of Co-amoxiclav for Prevention of Postoperative Complications in Dentoalveolar Surgery
CTID: NCT03844776
Phase: N/A    Status: Unknown status
Date: 2020-10-06
The Use of Prophylactic Antibiotics in Endoscopy Sinus Surgery for Chronic Rhinosinusitis With or Without Polyp
CTID: NCT03809312
Phase: Phase 4    Status: Unknown status
Date: 2020-07-14
Randomized Clinical Trial to Compare the Treatment of Mild Acute Diverticulitis With or Without Antibiotics
CTID: NCT02785549
Phase: Phase 4    Status: Completed
Date: 2020-05-14
Trial of Faropenem and Cefadroxil (in Combination With Amoxicillin/Clavulanic Acid and Standard TB Drugs) in Patients With Pulmonary Tuberculosis: Measurement of Early Bactericidal Activity and Effects on Novel Biomarkers
CTID: NCT02381470
Phase: Phase 2    Status: Completed
Date: 2020-03-23
The Amputation Surgical Site Infection Trial (ASSIT)
CTID: NCT02018094
Phase: Phase 4    Status: Completed
Date: 2019-07-15
Short (5 Days) Versus Long (14 Days) Duration of Antimicrobial Therapy for Acute Bacterial Sinusitis in Children
CTID: NCT01166945
Phase: N/A    Status: Completed
Date: 2019-06-10
Bioequivalence Study of Clavamox, Film-coated Tablets, 875 mg + 125 mg Pharmtechnology LLC, Belarus), and Augmentin®, Film-coated Tablets, 875 mg + 125 mg (GlaxoSmithKline Trading CJSC, Russia), in Healthy Volunteers Under Fasting Conditions
CTID: NCT03702894
Phase: Phase 1    Status: Completed
Date: 2019-05-14
Trial on the Ideal Duration of Oral Antibiotics in Children With Pneumonia
CTID: NCT02258763
Phase: Phase 4    Status: Completed
Date: 2019-04-23
Bioequivalence Study of Clavamox, Powder for Oral Suspension, 400 mg + 57 mg / 5 ml (Pharmtechnology LLC, Belarus), and Augmentin®, Powder for Oral Suspension, 400 mg + 57 mg / 5 ml (GlaxoSmithKline Trading CJSC, Russia), in Healthy Volunteers Under Fasting Conditions
CTID: NCT03616301
Phase: Phase 1    Status: Completed
Date: 2018-10-15
Does Antibiotics Use During Surgery Help to Decrease Wound Infection and Increase Success After Ear Surgery in Children
CTID: NCT03700814
Phase: Phase 4    Status: Completed
Date: 2018-10-10
Short Duration Treatment of Non-severe Community Acquired Pneumonia
CTID: NCT01963442
Phase: Phase 2    Status: Unknown status
Date: 2017-08-14
Study to Assess the Efficacy and Safety of Potassium Clavulanate/Amoxicillin in Children With Acute Bacterial Rhinosinusitis
CTID: NCT01934231
Phase: Phase 3    Status: Completed
Date: 2017-07-11
C
Shorter treatment of catheter related urinary tract infections
CTID: null
Phase: Phase 4    Status: Prematurely Ended
Date: 2018-03-07
The effect of rectal swab culture-guided antimicrobial prophylaxis in men undergoing prostate biopsy on infectious complications and cost of care: A randomized controlled trial in the Netherlands.
CTID: null
Phase: Phase 4    Status: Completed
Date: 2018-02-06
INTRAVENOUS-TO-ORAL ANTIBIOTIC SWITCH THERAPY FOR SUSPECTED NEONATAL BACTERIAL INFECTIONS:
CTID: null
Phase: Phase 4    Status: Completed
Date: 2017-06-23
Antibiotic treatment alone for children with acute appendicitis; a prospective cohort study part of the Antibiotic versus Primary Appendectomy for Children with acute appendicitis; the APAC trial.
CTID: null
Phase: Phase 3    Status: Completed
Date: 2017-05-18
Initial non-operative treatment strategy versus appendectomy treatment strategy for simple appendicitis in children aged 7-17 years old. APAC study
CTID: null
Phase: Phase 4    Status: Completed
Date: 2016-11-10
Multicentre controlled, randomized clinical trial to compare the efficacy and safety of ambulatory treatment of mild acute diverticulitis without antibiotics with the standard treatment with antibiotics
CTID: null
Phase: Phase 4    Status: Ongoing
Date: 2016-10-27
Evaluation of the efficacy of antibiotic therapy combined with corticosteroids in severe alcoholic hepatitis
CTID: null
Phase: Phase 3    Status: Ongoing
Date: 2016-07-25
ANODE: a randomised controlled trial of prophylactic ANtibiotics to investigate the prevention of infection following Operative vaginal DElivery.
CTID: null
Phase: Phase 4    Status: Completed
Date: 2015-10-29
A Phase 2/3, Randomized, Open-Label, Multi-center
CTID: null
Phase: Phase 2    Status: Temporarily Halted, Completed
Date: 2014-10-10
Multiple-dose pharmacokinetics of ampicillin / sulbactam and amoxicillin / clavulanic acid during haemodialysis in longterm haemodialysis patients
CTID: null
Phase: Phase 4    Status: Completed
Date: 2013-07-19
Neonatal and Paediatric Pharmacokinetics of Antimicrobials study
CTID: null
Phase: Phase 4    Status: GB - no longer in EU/EEA
Date: 2013-07-19
Are phrophylactic antibiotics necessary before laparoscopic living kidney donation? A double blind, randomised, controlled trial.
CTID: null
Phase: Phase 4    Status: Completed
Date: 2012-10-22
Pharmacokinetics of small spectcrum beta-lactam antibiotics (Amoxicillin/Clavulanic Acid and Cefuroxime) on intensive care.
CTID: null
Phase: Phase 4    Status: Completed
Date: 2012-03-09
Efficacy and Cost Efficacy of Prophylactic treatment with Antibiotics during concomitant chemoradiotherapy in patients with locally advanced head and neck cancer to prevent Aspiration Pneumonia.
CTID: null
Phase: Phase 2, Phase 3    Status: Ongoing
Date: 2011-11-15
A prospective single blind randomised controlled study to compare the outcomes of patients with diabetes and clinically non-infected ischaemic and neuropathic foot ulcers treated with and without oral antibiotics
CTID: null
Phase: Phase 4    Status: Prematurely Ended
Date: 2011-07-13
Place de l’antibiothérapie postopératoire dans la cholécystite aiguë lithiasique. Antibiothérapie postopératoire de courte durée versus absence d’antibiothérapie postopératoire
CTID: null
Phase: Phase 3    Status: Ongoing
Date: 2009-08-19
''A prospective, randomized, open label, active comparator, multicenter, national trial to compare the efficacy and safety of sequential IV/PO moxifloxacin 400 mg once daily versus IV amoxicillin/clavulanate 2,0/0,2 g every 8 hours followed by oral amoxicillin/clavulanate 875/125 mg every 8 hours in the treatment of adult subjects with complicated skin and skin structure infections''
CTID: null
Phase: Phase 3    Status: Prematurely Ended
Date: 2008-09-25
A national, prospective, randomized, open label study to asses the efficacy and safety of IV/PO moxifloxacin vs IV ceftriaxone + IV azithromicin followed by PO amoxicilline/clavulanate and PO claritromycin in subjects with community-acquired pneumonia
CTID: null
Phase: Phase 3    Status: Prematurely Ended
Date: 2007-12-10
Interaction médicamenteuse entre la warfarine (Coumadine®) et l’association amoxicilline-acide clavulanique (Augmentin®)
CTID: null
Phase: Phase 2    Status: Ongoing
Date: 2007-09-14
A prospective, randomized, open-label, active-controlled study in adult subjects with acute bacterial sinusitis comparing the clinical efficacy of telithromycin (KETEK®) 800 mg once a day for 5 days versus amoxicillin-clavulanic acid (AUGMENTIN®) 875/125 mg twice a day for 10 days.
CTID: null
Phase: Phase 4    Status: Completed
Date: 2004-11-16

Contact Us